Macro­Gen­ics vs Mer­ck: An un­der­dog plans a pre­mier bout with the heavy­weight cham­pi­on of the PD-1 class

Some­time dur­ing the fourth quar­ter of the year, Macro­Gen­ics is promis­ing to do some­thing that ap­par­ent­ly has nev­er been tried be­fore in the top­sy-turvy world of im­muno-on­col­o­gy. They’ll put their ex­per­i­men­tal PD-1 ther­a­py MGA012, part­nered with In­cyte, in­to a study that pits them head-to-head against Keytru­da/chemo — the rul­ing PD-1/(L)1 on the mar­ket to­day — for front­line head and neck can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER